FDA accepts Opus Genetics presbyopia drug application
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- US stock index futures subdued as oil, Treasury yields rise on Iran tensions
- Oil prices steady as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Dollar hits two-week high, Middle East conflict and rate paths in focus
- Is the ECB’s hawkish shift just beginning to bite? UBS weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
February 25, 2026 6:59 AM ESTRESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (Opus Genetics or the Company), a clinical-stage biopharmaceutical company... More
